P
3.59
-0.21 (-5.53%)
| Previous Close | 3.80 |
| Open | 3.72 |
| Volume | 622,930 |
| Avg. Volume (3M) | 1,255,427 |
| Market Cap | 316,865,216 |
| Price / Sales | 2.37 |
| Price / Book | 1.48 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Profit Margin | -96.06% |
| Operating Margin (TTM) | -107.81% |
| Diluted EPS (TTM) | -1.22 |
| Quarterly Revenue Growth (YOY) | -14.60% |
| Total Debt/Equity (MRQ) | 21.85% |
| Current Ratio (MRQ) | 6.52 |
| Operating Cash Flow (TTM) | -45.15 M |
| Levered Free Cash Flow (TTM) | -24.16 M |
| Return on Assets (TTM) | -17.23% |
| Return on Equity (TTM) | -48.91% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bearish |
| Diagnostics & Research (Global) | Mixed | Bearish | |
| Stock | Personalis, Inc. | Bearish | Bullish |
AIStockmoo Score
0.0
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.00 |
|
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 31.33% |
| % Held by Institutions | 42.73% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Blue Water Life Science Advisors, Lp | 31 Dec 2024 | 1,132,900 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 8.00 (HC Wainwright & Co., 122.84%) | Buy |
| 8.00 (Craig-Hallum, 122.84%) | Buy | |
| Median | 8.00 (122.84%) | |
| Low | 7.00 (Needham, 94.99%) | Buy |
| Average | 7.67 (113.65%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 3.66 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 10 Apr 2025 | 7.00 (94.99%) | Buy | 3.03 |
| 28 Feb 2025 | 7.00 (94.99%) | Buy | 4.14 | |
| Craig-Hallum | 17 Mar 2025 | 8.00 (122.84%) | Buy | 3.80 |
| HC Wainwright & Co. | 28 Feb 2025 | 8.00 (122.84%) | Buy | 4.14 |
| 27 Jan 2025 | 8.00 (122.84%) | Buy | 5.81 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Mar 2025 | Announcement | Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference |
| 03 Mar 2025 | Announcement | New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection |
| 27 Feb 2025 | Announcement | Personalis Reports Fourth Quarter and Full Year 2024 Financial Results |
| 18 Feb 2025 | Announcement | Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference |
| 13 Feb 2025 | Announcement | Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results |
| 28 Jan 2025 | Announcement | Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference |
| 13 Jan 2025 | Announcement | New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |